Pharma Journalist -

Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug and pediatric exclusivity to CRESEMBA (isavuconazonium sulfate) for the…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned…
Read More...

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA…
Read More...

Johnson & Johnson announced it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology…
Read More...

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company broke ground on a major expansion…
Read More...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment…
Read More...

Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), announced the closing of a…
Read More...

Gilead Sciences, Inc. and Merus N.V. announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific…
Read More...

Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of a Type II variation application to the European Medicines Agency (EMA). The submission is…
Read More...

Sandoz, the global leader in generic and biosimilar medicines, announced that the US Food and Drug Administration (FDA) approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz),…
Read More...